The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection
Open accessPublished version of a preprint
Abstract
Following emergence in late 2019, SARS-CoV-2 rapidly became pandemic and is presently responsible for millions of infections and hundreds of thousands of deaths worldwide. There is currently no approved vaccine to halt the spread of SARS-CoV-2 and only very few treatment options are available to manage COVID-19 patients. For development of preclinical countermeasures, reliable and well-characterized small animal disease models will be of paramount importance. Here we show that intranasal inoculation of SARS-CoV-2 into Syrian hamsters consistently caused moderate broncho-interstitial pneumonia, with high viral lung loads and extensive virus shedding, but animals only displayed transient mild disease. We determined the infectious dose 50 to be only five infectious particles, making the Syrian hamster a highly susceptible model for SARS-CoV-2 infection. Neither hamster age nor sex had any impact on the severity of disease or course of infection. Finally, prolonged viral persistence in interleukin 2 receptor gamma chain knockout hamsters revealed susceptibility of SARS-CoV-2 to adaptive immune control. In conclusion, the Syrian hamster is highly susceptible to SARS-CoV-2 making it a very suitable infection model for COVID-19 countermeasure development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 1×
“ing enzyme 2 (ACE-2) receptor has only low affinity for the SARS-CoV-2 spike protein leading to poor binding and entry [20,21].”
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Self-citationNetland, J., Meyerholz, D. K., Moore, S., Cassell, M., & Perlman, S. (2008) · Journal of Virology · doi:10.1128/jvi.00737-08 · Cited by 1,293
Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus
McCray, P. B., Pewe, L., Wohlford-Lenane, C., Hickey, M., Manzel, L., Shi, L., Netland, J., Jia, H. P., Halabi, C., Sigmund, C. D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02012-06 · Cited by 1,010
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762
Respiratory disease in rhesus macaques inoculated with SARS-CoV-2
Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720
Self-citationA mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2708-8 · Cited by 675
Research works printed but not linked: 31
- 10.1016/S0140-6736(20)30211-7 · DOI · Paper page
- 10.1001/jama.2020.1585 · DOI · Paper page
- 10.1016/j.ijantimicag.2020.105949 · DOI · Paper page
- Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836.
- Ali MJ, Hanif M, Haider MA, et al. Treatment options for COVID-19: a review. Front Med (Lausanne). 2020;7(480).
- 10.3851/IMP3368 · doi:10.3851/imp3368
- 10.1101/2020.05.14.096727 · DOI
- 10.1016/j.chom.2020.03.023 · DOI · Paper page
- 10.1016/S2666-5247(20)30089-6 · DOI · Paper page
- 10.1126/science.abb7015 · DOI · Paper page
- 10.1038/s41586-020-2312-y · DOI · Paper page
- 10.1073/pnas.2009799117 · DOI · Paper page
- 10.1101/2020.05.02.073411 · DOI
- 10.1038/s41586-020-2342-5 · DOI · Paper page
- 10.1016/j.cell.2020.06.011 · DOI · Paper page
- 10.1101/2020.05.27.118893 · DOI
- 10.1128/JVI.01702-06 · DOI · Paper page
- 10.1016/j.chom.2020.05.020 · DOI · Paper page
- 10.1007/s13238-020-00767-x · DOI
- 10.3201/eid2606.200516 · DOI · Paper page
- 10.1242/dmm.044602 · DOI
- 10.1093/oxfordjournals.aje.a118408 · DOI · Paper page
- 10.2807/1560-7917.ES.2020.25.3.2000045 · DOI · Paper page
- 10.1038/s41586-020-2012-7 · DOI · Paper page
- 10.1101/2020.06.29.177154 · doi:10.1101/2020.06.29.177154
- 10.1016/j.immuni.2019.03.028 · DOI · Paper page
- Allenspach E, Rawlings DJ, Scharenberg AM, et al. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, editor. X-linked severe combined immunodeficiency. Seattle, WA: GeneReviews((R)); 1993.
- 10.3390/ijms21082948 · DOI · Paper page
- Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34(2).
- 10.3345/cep.2020.00493 · DOI · Paper page
- 10.1016/j.cell.2020.05.027 · DOI · Paper page
Cited by
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
Killingley, B., Mann, A. J., Kalinova, M., Boyers, A., Goonawardane, N., Zhou, J., Lindsell, K., Hare, S. S., Brown, J., Frise, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01780-9 · Cited by 530
Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.026 · Cited by 366
Cox, R. M., Wolf, J. D., & Plemper, R. K. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00835-2 · Cited by 387
Lin, Y.-C., Malott, R. J., Ward, L., Kiplagat, L., Pabbaraju, K., Gill, K., Berenger, B. M., Hu, J., Fonseca, K., Noyce, R. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09218-5 · Cited by 74
Infectious SARS-CoV-2 Is Emitted in Aerosol Particles
Hawks, S. A., Prussin, A. J., Kuchinsky, S. C., Pan, J., Marr, L. C., & Duggal, N. K. (2021) · mBio · doi:10.1128/mbio.02527-21 · Cited by 57
Metadata
- Authors
- Rosenke, K., Meade-White, K., Letko, M., Clancy, C., Hansen, F., Liu, Y., Okumura, A., Tang-Huau, T.-L., Li, R., Saturday, G., Feldmann, F., Scott, D., Wang, Z., Munster, V., Jarvis, M. A., & Feldmann, H.
- Venue
- Emerging Microbes & Infections
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 9
- Issue
- 1
- Pages
- 2673-2684
- ISSN
- 2222-1751 (ISSN-L)
- OpenAlex
- W3107525025
- Cited by
- 229
- References
- 9
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Institutes of Allergy and Infectious Diseases
- National Institutes of Health
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1080/22221751.2020.1858177
- The paper
- Rosenke, K., Meade-White, K., Letko, M., Clancy, C., Hansen, F., Liu, Y., Okumura, A., Tang-Huau, T.-L., Li, R., Saturday, G., Feldmann, F., Scott, D., Wang, Z., Munster, V., Jarvis, M. A., & Feldmann, H. (2020). Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerging Microbes & Infections. https://doi.org/10.1080/22221751.2020.1858177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.